Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Aleksandra Butrym(Wroclaw Medical University), Grzegorz Mazur(Wroclaw Medical University), Andrzej Mital(Gdańsk Medical University), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Justyna Rybka(Hospital Universitari i Politècnic La Fe), Krzysztof Mądry(Medical University of Warsaw), Maria Bieniaszewska(Gdańsk Medical University), Elżbieta Patkowska(Institute for Transfusion Medicine), Beata Kumiega(Lublin Oncology Center), Ryszard Wichary(Medical University of Silesia), Tigran Torosian(Medical University of Warsaw), Krzysztof Warzocha(Instytut Hematologii i Transfuzjologi)
Cited by 7
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
|New England Journal of Medicine|2020|432